Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV MelanomaAxel Hauschild, Ulrich Keilholz, Alexander M.M. Eggermont et al.|Journal of Clinical Oncology|2009Cited by 545
Emerging drugs for the treatment of vitiligoPriyanka Karagaiah, Torello Lotti, Yan Valle et al.|Expert Opinion on Emerging Drugs|2020Cited by 75
Adjuvant therapy with nivolumab versus placebo in patients with resected stage IIB/C melanoma (CheckMate 76K)Georgina V. Long, John M. Kirkwood, Michele Del Vecchio et al.|SKIN The Journal of Cutaneous Medicine|2023Cited by 25